Medtronic Study Finds Opioid-Induced Respiratory Depression in the Hospital More Common and Costly
14 September 2020 Release date 10 September 2020 PRODIGY Study Provides First Validated Risk Prediction Tool to Guide Continuous Monitoring for Opioid-Induced Respiratory Depression (OIRD) OIRD Occurred in 46% of Patients Studied Patients with Respiratory Depression Are 37%…
Gilead Sciences to Acquire Immunomedics
13 September 2020 Gilead Adds TrodelvyTM, First-in-Class Antibody-Drug Conjugate Approved to Treat Triple-Negative Breast Cancer, With Promise in Other Forms of Breast Cancer and Additional Solid Tumors Acquisition Transforms Gilead’s Portfolio with First-in-Class Commercial Product with Significant Revenue and…
Electronic Signatures and Clinical Trial Research Agreement execution in Australia
14 September 2020 Release date 12 September 2020 CT:IQ together with Medicines Australia (MA), Medical Technology Association of Australia (MTAA) and AusBiotech have released a joint position statement confirming that eSignatures can be used to execute clinical trial…
Levitas Bio partners with Planet Innovation to develop and manufacture the world’s first label-free cell separation platform
14 September 2020 Silicon Valley start-up Levitas Bio has launched the world’s first label-free cell separation platform, the LeviCell™. The benchtop device uses revolutionary magnetic levitation technology developed at Stanford University to sort cell populations, without modifying the cells with…
Supporting Victorian Businesses On Our Road To COVID Normal
13 September 2020 Read the original media release here. A massive new support package will see $3 billion in cash grants, tax relief and cashflow support delivered to Victorian businesses as we work together to drive coronavirus cases…
Impact to R&D Tax Incentive claims by COVID-19 or Bushfires 2019-20
11 September 2020 This information is provided by AusIndustry. Read more via AusIndustry here. Aware that COVID-19 and the recent bushfires may have affected your economic circumstances, applications for the Research and Development Tax Incentive have been extended…
Opthea Appoints US-Based Non-Executive Director
10 September 2020 The directors of Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, are pleased to announce the appointment of Mr Daniel Spiegelman as an…
Locked And Loaded: Using Genomic Sequencing To Target Covid-19’s Weak Spots
10 September 2020 Originally published via the University of Melbourne by Stephanie Portelli, Elston D’Souza and Associate Professor David Ascher COVID-3D, a new open-access tool harnesses SARS-CoV-2 genomic and structural information to help ensure therapeutic efforts remain effective.…
Noxopharm Appoints New Chair
10 September 2020 Release date 9 September 2020 Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announces the appointment of Mr Fred Bart as Non-Executive Chair, allowing ExecutiveChair and CEO, Dr Graham Kelly, to focus on the CEO…
Local Response Units And Boosted Reporting For Safe Next Steps
10 September 2020 Release date 8 September 2020 New Suburban Response Units will be set up to give rapid local insights and leverage community connections to help keep localised outbreaks contained, as Victoria takes the first steps to…
Global CRO To Execute Noxopharm DARRT-2 Prostate Cancer Study
10 September 2020 Release date 8 September 2020 Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce that after a rigorous global search, the clinical research organisation (CRO), Parexel® Biotech, has been appointed to manage…
Allens: Capturing the hydrogen opportunity for Australia and Japan
10 September 2020 Now is the time to look for future global opportunities Australia’s hydrogen industry is expected to contribute at least $11 billion to the national economy and generate around 7,600 jobs by 2050. In the current state of play,…
